From BigGo Finance · BigGo Finance · · 1m 20s
HLB Innovation CAR-T Therapy Shows Response in 4 of 5 Lymphoma Patients
HLB Innovation's CAR-T therapy SynKIR-310 achieved 80% response rate in relapsed lymphoma patients at ASH 2026 presentation.
In brief
HLB Innovation's CAR-T therapy SynKIR-310 achieved 80% response rate in relapsed lymphoma patients at ASH 2026 presentation. HLB Innovation's US subsidiary Verismo Therapeutics reported 80% objective response rate for its CAR-T therapy SynKIR-310 in relapsed lymphoma patients. Originally reported by BigGo Finance.
Verismo Therapeutics Results
Verismo Therapeutics, the US subsidiary of South Korea's HLB Innovation, disclosed interim Phase 1 results for its relapsed/refractory B-cell non-Hodgkin lymphoma treatment SynKIR-310.
Response Rate Achieved
Four of five evaluable patients responded, with three achieving complete responses and no cytokine release syndrome or ICANS reported.
Safety Profile
None of the six patients in the first two dose cohorts reported cytokine release syndrome or ICANS, and no dose-limiting toxicities were observed.
ASH 2026 Presentation
The data will be presented orally at the American Society of Hematology annual meeting (ASH 2026) in New Orleans on December 12.
KIR-CAR Platform
Brian Kim, CEO and co-founder, described KIR-CAR as a proprietary platform to reduce excessive immune response and early T-cell exhaustion in CAR-T therapies.
South Korean Companies Presenting
South Korea's LigaChem Biosciences, GC Cell, and Curocell will also present clinical results for blood cancer therapies at ASH 2026.
Next Steps for Verismo
Verismo plans to disclose third cohort results and pharmacokinetic data at ASH 2026 to confirm dose-response relationship.
The one thing
HLB Innovation's US subsidiary Verismo Therapeutics reported 80% objective response rate for its CAR-T therapy SynKIR-310 in relapsed lymphoma patients.
